A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy

PHASE2CompletedINTERVENTIONAL
Enrollment

367

Participants

Timeline

Start Date

October 29, 2024

Primary Completion Date

May 27, 2025

Study Completion Date

May 27, 2025

Conditions
Acute Pain
Interventions
DRUG

VX-993

Tablets for oral administration.

DRUG

HB/APAP

Capsules for oral administration.

DRUG

Placebo (matched to VX-993)

Placebo matched to VX-993 for oral administration.

DRUG

Placebo (matched to HB/APAP)

Placebo matched to HB/APAP for oral administration.

Trial Locations (14)

30331

Atlanta Center for Medical Research, Atlanta

33172

Clinical Pharmacology of Miami, Miami

33613

ForCare Clinical Research, Tampa

35660

Shoals Medical Trials Inc., Sheffield

72211

Woodland International Research Group, Little Rock

77043

Memorial Hermann Village, Houston

78240

Endeavor Clinical Trials, San Antonio

78759

BioBehavioral Research of Austin, Austin

84107

JBR Clinical Research, Salt Lake City

85053

Arizona Research Center, Phoenix

93301

Trovare Clinical Research, Bakersfield

California

"New Hope Research Development , Tarzana, CA"

Texas

"HD Research LLC , First Surgical Hospital"

"HD Research LLC , Legent Orthopedic Hospital"

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT06619847 - A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy | Biotech Hunter | Biotech Hunter